Device Improves Safety and Accuracy of Capillary Blood Collection

A newly launched device improves the safety, accuracy, and turnaround time of capillary blood collection and testing in patients with fragile veins that can be difficult to access, such as infants, children, oncology patients, and the elderly.

The preanalytical phase is a critical step in the diagnostic process, with significant impact to patient health, healthcare worker safety, and workflow efficiencies. Historically, low-volume capillary blood collection has increased test result turnaround time due to incompatibility with automated testing instruments and a higher risk of patient identification errors. The new product is fully compatible with most automated hematology instruments, reducing turnaround time and costs associated with sample transfer and relabeling.

The new BD (Franklin Lakes, NJ, USA) microtainer MAP tube is a low-volume collection system that accommodates standard, full-size patient identification labels. Traditional microcollection tubes are incompatible with standard labels due to their size. This can lead to dangerous labeling errors that can result in misdiagnosis and incorrect patient treatment.

The design of the microtainer MAP tube enables automated processing with 81% less blood than venous systems, improving test turnaround time and laboratory efficiency. This is a critical improvement for patients from whom it is difficult to obtain a sufficient blood sample to perform critical diagnostic tests.

BD is a global medical technology company that develops, manufactures, and sells medical devices, instrument systems, and reagents. The company is focused on enhancing the quality and speed of diagnosing infectious diseases and cancers, improving drug delivery, and advancing research, discovery and production of new drugs and vaccines.

Related Links:
BD